GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed Price. Currency in GBp
1,486.80
-0.80 (-0.05%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close1,487.60
Open1,483.00
Bid1,470.00 x 175400
Ask1,515.00 x 417900
Day's Range1,475.80 - 1,497.20
52 Week Range1,236.40 - 1,625.00
Volume6,426,495
Avg. Volume9,057,910
Market Cap73.06B
Beta1.05
PE Ratio (TTM)44.51
EPS (TTM)33.40
Earnings DateOct 31, 2018
Forward Dividend & Yield0.76 (5.12%)
Ex-Dividend Date2018-08-09
1y Target Est1,646.82
  • Reuters1 hour ago

    PRESS DIGEST- Financial Times - Sept 19

    The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Brussels threatens legal action against UK over customs ...

  • Reuters5 hours ago

    Deals of the day-Mergers and acquisitions

    ** Coca-Cola Co said it bought Australia-based Organic & Raw Trading Co, known for its Mojo brand of kombucha tea, extending its push into healthier drinks. ** Nestle, Unilever, and Coca-Cola are among bidders for GlaxoSmithKline's Indian Horlicks nutrition business, expected to fetch more than $4 billion, four people familiar with the matter said. ** U.S.-based recreational vehicle maker Thor Industries has agreed to buy German family-owned peer Erwin Hymer Group in a deal valuing the company at 2.1 billion euros ($2.45 billion)including debt, Thor said.

  • Exclusive: Nestle, Unilever, Coke make bids in $4 billion-plus GSK India sale - sources
    Reuters6 hours ago

    Exclusive: Nestle, Unilever, Coke make bids in $4 billion-plus GSK India sale - sources

    Nestle (NESN.S), Unilever (ULVR.L) (UNc.AS) and Coca-Cola (KO.N) are among bidders for GlaxoSmithKline's (GSK.L) Indian Horlicks nutrition business, expected to fetch more than $4 billion, four people familiar with the matter said.

  • Reuters9 hours ago

    GSK grabs new drug development head from Boehringer

    LONDON (Reuters) - GlaxoSmithKline (GSK.L) has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development as the company reshapes its research ...

  • Exclusive - Nestle, Unilever, Coke make bids in $4 billion-plus GSK India sale: sources
    Reuters9 hours ago

    Exclusive - Nestle, Unilever, Coke make bids in $4 billion-plus GSK India sale: sources

    Nestle (NESN.S), Unilever (ULVR.L) (UNc.AS) and Coca-Cola (KO.N) are among bidders for GlaxoSmithKline's (GSK.L) Indian Horlicks nutrition business, expected to fetch more than $4 billion (3.03 billion pounds), four people familiar with the matter said. It was not clear which other companies were bidding, although Reckitt Benckiser (RB.L), a company eager to build up its consumer health operation, did not make an offer, two sources said. GSK, Nestle, Reckitt and Unilever declined to comment.

  • Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
    Market Realist14 hours ago

    Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio

    In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.

  • Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
    Zacksyesterday

    Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

    Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.

  • A Look at the Market Caps of the Pharma Stocks under Review
    Market Realistyesterday

    A Look at the Market Caps of the Pharma Stocks under Review

    As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.

  • Is Artificial Intelligence the Next Big Thing in Biotech?
    Zacks2 days ago

    Is Artificial Intelligence the Next Big Thing in Biotech?

    Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.

  • Associated Press4 days ago

    Chinese scientist pleads guilty in plot to steal GSK secrets

    PHILADELPHIA (AP) — A Chinese scientist has pleaded guilty to conspiring to steal biopharmaceutical trade secrets from GlaxoSmithKline in what prosecutors said was a scheme to set up companies in China to market them.

  • Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
    Zacks4 days ago

    Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

    Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

  • Johnson & Johnson’s Recent Development in HIV
    Market Realist4 days ago

    Johnson & Johnson’s Recent Development in HIV

    On August 15, Johnson & Johnson (JNJ) and ViiV Healthcare, the HIV business subsidiary of GlaxoSmithKline (GSK), announced positive top-line results of their Phase 3 ATLAS (Antiretroviral Therapy as Long-Acting Suppression) trial. The regimen consists of Johnson & Johnson’s rilpivirine and ViiV Healthcare’s cabotegravir, which is injected once per month. The study evaluated this 2DR therapy with the standard of care three-drug daily oral regimen.

  • Johnson & Johnson: Analyst Recommendations and Target Price
    Market Realist6 days ago

    Johnson & Johnson: Analyst Recommendations and Target Price

    Johnson & Johnson (JNJ) is one of the major healthcare companies in the world. It operates through its pharmaceuticals, medical devices, and consumer business segments. Although its pharmaceutical business generates most of its sales, medical devices and consumer business include a number of leading brands in their respective market spaces.

  • What's Next for Gilead Sciences After Its Latest Clinical Success
    Motley Fool6 days ago

    What's Next for Gilead Sciences After Its Latest Clinical Success

    Gilead executives talk about the future after reporting positive late-stage results for the company's experimental rheumatoid arthritis drug.

  • Coca-Cola May Have a New Target in Its Race for Global Beverage Dominance
    Motley Fool8 days ago

    Coca-Cola May Have a New Target in Its Race for Global Beverage Dominance

    The company is reported to be a bidder for a different type of drink.

  • Zacks8 days ago

    Glaxo's Nucala Suffers Regulatory Setback, Gets CRL for COPD

    FDA issues a complete response letter to Glaxo's (GSK) application for label expansion of its asthma drug, Nucala for COPD.

  • Motley Fool10 days ago

    3 Top Value Stocks to Buy in September

    Looking for bargains this fall? These three stocks could fit the bill.

  • Coca-Cola Plans to Bid for GSK's Horlicks: Sunday Telegraph
    Bloomberg10 days ago

    Coca-Cola Plans to Bid for GSK's Horlicks: Sunday Telegraph

    The Coca-Cola Co. is moving forward with its interest in GlaxoSmithKline Plc’s Indian malted milk drink company Horlicks Ltd, according to the Sunday Telegraph.

  • Reuters11 days ago

    GSK says U.S. FDA wants more information on pulmonary drug

    GlaxoSmithKline (GSK.L) said on Friday that U.S. health authorities had asked for more information about its Nucala drug for use in combating chronic obstructive pulmonary disease (COPD). GSK said it had received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its application for mepolizumab - the generic name for Nucala - as an add-on treatment to inhaled corticosteroid-based maintenance treatment.

  • Reuters11 days ago

    GSK says U.S. FDA wants more information on pulmonary drug

    GlaxoSmithKline said on Friday that U.S. health authorities had asked for more information about its Nucala drug for use in combating chronic obstructive pulmonary disease (COPD). GSK said it had received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its application for mepolizumab - the generic name for Nucala - as an add-on treatment to inhaled corticosteroid-based maintenance treatment.

  • Benzinga11 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tesla Inc (NASDAQ: TSLA ) stock was trading lower ...

  • Benzinga12 days ago

    The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 6) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(announced positive ...

  • Novartis to Divest Portions of Sandoz US to Aurobindo
    Market Realist12 days ago

    Novartis to Divest Portions of Sandoz US to Aurobindo

    Novartis (NVS) announced today, September 6, that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA for $0.9 billion in cash and $0.1 billion in potential earn-outs. The select portions include the Sandoz US dermatology business and the generic US oral solids business. The deal includes ~300 products and additional development programs that will be transferred from Sandoz’s US portfolio to Aurobindo.

  • Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo
    Reuters12 days ago

    Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

    ZURICH/BENGALURU (Reuters) - New Novartis (NOVN.S) Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd (ARBN.NS) for up to $1 billion. The deal, which comes after price pressure hurt the U.S. pills business, includes some 300 products. Novartis said the transaction will result in a roughly $70 million impairment, to be confirmed when it releases third-quarter results in October.

  • CNBC13 days ago

    Stocks making the biggest move premarket: CBS, XOM, FB, DAL, NAV & more

    These are the stocks posting the largest moves before the bell.